Environmental Factors Can Alter Mammalian Sex Determination, Study Finds

Researchers in Japan have initiated clinical trials for a groundbreaking universal artificial blood product that could be compatible with all blood types. Led by Professor Hiromi Sakai at Nara Medical University, the artificial blood could have a shelf life of up to two years, addressing the critical shortages and compatibility issues associated with traditional blood donations, which typically last only 42 days, according to a report by Newsweek.
The creation process involves encasing haemoglobin from expired donor blood in a protective shell, resulting in stable and virus-free artificial red blood cells. In March, the team administered doses ranging from 100 to 400 milliliters of this artificial blood to 16 healthy adult volunteers to assess its safety and efficacy. If successful, widespread clinical use could be expected by 2030, making Japan the first country to employ such a product in medical care.
Professor Sakai emphasized the urgent need for artificial blood alternatives, stating, "there is currently no safe substitute for red cells." The potential implications have sparked excitement on social media, with many calling it a transformative endeavor that could revolutionize emergency medicine.